Adenoid Cystic Carcinoma clinical trials at UCSF
3 in progress, 1 open to eligible people
Adenoid Cystic Carcinoma is a rare type of cancer. UCSF is studying how a special type of treatment, called Stereotactic Body Radiotherapy (SBRT), can help. The focus of this study is to understand the effects of starting this treatment early.
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial
open to eligible people ages 18 years and up
The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival. The name(s) of the study intervention involved in this study is: - Stereotactic Body Radiation Therapy (SBRT)
San Francisco, California and other locations
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Sorry, in progress, not accepting new patients
An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.
San Francisco, California and other locations
REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Sorry, not currently recruiting here
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)
San Francisco, California and other locations
Our lead scientists for Adenoid Cystic Carcinoma research studies include Hyunseok Kang, MD David Oh Sue Yom, MD, PhD.
Last updated: